TAMERA J. LILLEMOE, M.D.

  Abbott Northwestern Hospital Laboratory

800 E 28th St
Minneapolis, MN 55407

(612) 863-4540

fax (612) 863-8375

My interest in breast pathology began during my residency, where I was fortunate to be mentored by Dr. Charles Horwitz.  Shortly after becoming a pathologist at Abbott Northwestern Hospital, I became the lead pathologist for the then developing Piper Breast Center (PBC).  During this time, I worked with PBC physicians, developing protocols and creating standards of practice for our multidisciplinary approach to breast care.  The PBC opened its doors in 1994, and was the first breast center in the state of Minnesota.  I have remained the lead pathologist for the breast center, and am one of the co-directors of the weekly PBC multidisciplinary conference for physicians, nurses and technologists.  I have participated in various research projects in breast cancer, and have given numerous lectures on breast pathology.  I am also director of the Allina Immunohistochemistry Lab, which performs an integral role in assessing benign and malignant breast tissue, while providing various prognostic information on breast cancers.   I remain committed to ensuring the best diagnostic capabilities for our breast patients.

PROFESSIONAL TRAINING AND EXPERIENCE

• Staff Pathologist, Hospital Pathology Associates, 1991 - present 

EDUCATION  

• Fellowship, Surgical Pathology, University of Minnesota, 1989-1990

• Residency, Pathology (Combined Anatomic and Clinical), 1985-1990

• Medical School, University of Minnesota, Minneapolis, MN, 1985

• Undergraduate, University of South Dakota

HONORS & AWARDS

• Chief Resident of Pathology, 1989-1990

• ASCP/CAP Resident’s Research Award, ASCP/CAP Fall Meeting, Las Vegas, Nevada, 1988

• Kenneth Ernst Research Award, Laboratory Medicine and Pathology Department, University of Minnesota, 1988

PROFESSIONAL CERTIFICATIONS

• Anatomic and Clinical Pathology

LICENSURE

• State of Minnesota - 1986

PROFESSIONAL AFFILIATIONS

• American Society of Breast Disease

• American Society of Clinical Pathology

• National Association of Immunohistochemistry

• Hennepin County Medical Society

• Minnesota Medical Association

• Minnesota Society of Pathologists

PUBLICATIONS

• McCormick, S.R., Lillemoe T.J., Beneke J., Schrauth J., Reinartz J.: HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and Path Vysion commercial assays. [Journal Article] American Journal of Clinical Pathology. 117(6):345-43, 2002.

• Gulbahce H.E., Lindeland A.T., Engel W., Lillemoe T.J.:  Metastatic Leydig cell tumor with sarcomatoid differentiation.  Arch Path Lab Med, 123 (11): 1104-7, Nov. 1999.

• Bostick R.M., Fosdick L., Grandits G.A., Lillemoe T.J., Wood J.R., Grambsh P., Louis T.A., Potter J.D.:  Colorectal epithelial cell proliferative kinetics and risk factors for colon cancer in sporadic adenoma patients.  Cancer Epidemiol Biomarkers, 6 (12):  1011-9, Dec. 1997.

• Bostick R.M., Fosdick L., Lillemoe T.J., Overn P., Wood J.R., Grambsch P., Elmer P., Potter J.D.:  Methodological findings and considerations in measuring colorectal epithelial cell proliferation in humans.  Cancer Epidemiol Biomarkers, 6 (11): 931-42, Nov. 1997.

• Bostick R., Fosdick L., Wood J., Grambsch P., Grandits G., Lillemoe T., Louis T., Potter J.: Calcium and Colorectal Epithelial Cell Proliferation in Sporadic Adenoma Patients:  A Randomized, Double-Blinded, Placebo- Controlled Clinical Trial.  Journal of the National Cancer Institute, Col 87 (17): 1307-1315, 1995.

• Abenoza P., Lillemoe T.:  CD34 and Factor XIIIa in the Differential Diagnosis of Dermatofibroma and Dermatofibrosarcoma Protuberans.  The American Journal of Dermatopathology, Vol. 15 (5): 429-434, 1993.

• Lillemoe T.J., Perrone T., Norris H.J., Dehner L.P.:  Myogenous phenotype of epithelial-like areas in endometrial stromal sarcomas.  Arch Pathol Lab Med, 1991; 115: 215-219.

• Swanson P.E., Lillemoe T.J., Pettinato G., Manivel J.C.:  Gross cystic disease fluid protein - 15 in salivary gland neoplasms.  Arch Pathol Lab Med, 1991; 115: 158-163.

• Wick M.R., Lillemoe T.J., Copland G.C., Swanson P.E., Manivel J.C., Kiang D.T.:  Gross cystic disease fluid protein – 15 as a marker for breast cancer; immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin.  Human Pathology 20:  281-287, 1989.